相似文献
1
Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options.
Pharmacol Ther. 2022 Sep;237:108253. doi: 10.1016/j.pharmthera.2022.108253. Epub 2022 Jul 21.
2
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19.
3
Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
Int J Mol Sci. 2020 Nov 24;21(23):8905. doi: 10.3390/ijms21238905.
4
Triple-negative breast cancer: advancements in characterization and treatment approach.
Curr Opin Obstet Gynecol. 2016 Feb;28(1):59-69. doi: 10.1097/GCO.0000000000000239.
5
Programmed cell death-related prognostic genes mediate dysregulation of the immune microenvironment in triple-negative breast cancer.
Front Immunol. 2025 Mar 12;16:1563630. doi: 10.3389/fimmu.2025.1563630. eCollection 2025.
6
Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment.
Pharmacol Res. 2024 Jun;204:107205. doi: 10.1016/j.phrs.2024.107205. Epub 2024 May 6.
7
Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer.
Cancer Genomics Proteomics. 2024 May-Jun;21(3):316-326. doi: 10.21873/cgp.20450.
8
Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Clin Epigenetics. 2018 Jun 27;10:88. doi: 10.1186/s13148-018-0514-z. eCollection 2018.
9
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Curr Treat Options Oncol. 2021 Mar 20;22(5):38. doi: 10.1007/s11864-021-00833-4.
10
Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors.
PeerJ. 2023 Jun 12;11:e15350. doi: 10.7717/peerj.15350. eCollection 2023.
引用本文的文献
1
The Prediction Model for Triple-Negative Breast Cancer Prognosis and Immunotherapy Efficacy Based on Single-Cell Sequencing of CD8+ T cells.
J Cancer. 2025 Jul 24;16(11):3343-3354. doi: 10.7150/jca.115507. eCollection 2025.
2
Targeting Reticulin 4 (RTN4) Within Small Extracellular Vesicles Combats Metastasis and Reinforces Immunotherapy in Triple-Negative Breast Cancer.
J Extracell Vesicles. 2025 Aug;14(8):e70154. doi: 10.1002/jev2.70154.
3
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer.
NPJ Breast Cancer. 2025 Aug 8;11(1):87. doi: 10.1038/s41523-025-00806-y.
4
Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer.
Eur J Med Res. 2025 Aug 4;30(1):704. doi: 10.1186/s40001-025-02998-2.
5
Quercetin: A Natural Ally in Combating Breast Cancer.
Int J Nanomedicine. 2025 Jul 19;20:9155-9177. doi: 10.2147/IJN.S518174. eCollection 2025.
6
Preoperative inflammatory status as a positive prognostic factor for triple-negative breast cancer patients receiving neoadjuvant therapy.
Medicine (Baltimore). 2025 Jul 11;104(28):e42208. doi: 10.1097/MD.0000000000042208.
7
Artificial intelligence-driven discovery of YH395A: A novel TGFβR1 inhibitor with potent anti-tumor activity against triple-negative breast cancer.
Cell Commun Signal. 2025 Jul 8;23(1):326. doi: 10.1186/s12964-025-02337-2.
8
Immune-based molecular subtyping of triple-negative breast cancer via SNF-CC and functional validation of key immune-associated genes.
Funct Integr Genomics. 2025 Jul 8;25(1):148. doi: 10.1007/s10142-025-01654-6.
9
Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance.
J Hematol Oncol. 2025 Jul 2;18(1):70. doi: 10.1186/s13045-025-01722-1.
10
A 'two-missile' nanoplatform for targeting triple-negative breast cancer: prodrug activation and immune enhancement.
Mater Today Bio. 2025 May 20;32:101891. doi: 10.1016/j.mtbio.2025.101891. eCollection 2025 Jun.
本文引用的文献
1
Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer.
Cancer Res. 2022 Jun 15;82(12):2281-2297. doi: 10.1158/0008-5472.CAN-21-3714.
2
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
3
MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells.
Mol Cancer Res. 2022 Apr 1;20(4):556-567. doi: 10.1158/1541-7786.MCR-21-0672.
4
Hallmarks of Cancer: New Dimensions.
Cancer Discov. 2022 Jan;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059.
5
Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
J Clin Oncol. 2022 Apr 1;40(10):1051-1058. doi: 10.1200/JCO.21.02054. Epub 2022 Jan 12.
6
Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer.
Clin Epigenetics. 2021 Dec 18;13(1):226. doi: 10.1186/s13148-021-01210-6.
7
New data for sacituzumab govitecan-hziy in the treatment of metastatic triple-negative breast cancer.
Clin Adv Hematol Oncol. 2021 Nov;19(11):723-725.
8
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113. doi: 10.1038/s41571-021-00565-2. Epub 2021 Nov 9.
9
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes.
Nat Commun. 2021 Nov 1;12(1):6276. doi: 10.1038/s41467-021-26502-6.
10
Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.
Sci Transl Med. 2021 Oct 27;13(617):eabe6201. doi: 10.1126/scitranslmed.abe6201.
Zotero 插件